Literature DB >> 30417279

A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.

Daniela Mikhaylov1, Ana Pavel1, Christopher Yao1, Grace Kimmel1, John Nia1, Peter Hashim1, Anjali S Vekaria1, Mark Taliercio1, Giselle Singer1, Rachel Karalekas1, Danielle Baum1, Yasaman Mansouri1, Mark G Lebwohl1, Emma Guttman-Yassky2,3,4.   

Abstract

Alopecia areata (AA) is a common autoimmune disease that results in non-scarring hair loss. AA pathogenesis is thought to involve multiple inflammatory cytokines. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces pro-inflammatory cytokine production. Recent studies demonstrate upregulation of PDE4 in human scalp lesions of AA patients and hair regrowth in a humanized AA mouse model upon apremilast treatment, suggesting a possible potential of apremilast in AA. To assess the efficacy and safety of apremilast in AA, we conducted a double-blind, placebo-controlled single-center pilot study in 30 moderate-to-severe AA patients (≥ 50% scalp involvement) that were randomized 2:1 to receive apremilast (n = 20) or placebo (n = 10) orally for 24 weeks. The primary endpoint was the percentage of patients achieving 50% reduction in severity of alopecia tool (SALT) score (SALT50) at 24 weeks compared to baseline, and the secondary endpoints included the percent change in SALT score at weeks 24 and 48. Eight patients in the apremilast arm withdrew prior to week 24 along with two patients in the placebo group, mostly due to lack of efficacy and adverse events. At 24 weeks, only 1 of 12 apremilast-treated subjects achieved SALT50, and similarly 1 of 8 placebo-treated subjects achieved SALT50. The difference between the mean percent improvement in SALT score at week 24 compared to baseline of the two study arms was not statistically significant (p = 0.38). The lack of treatment response in most of our patients argues against a pathogenic role for PDE4 specifically in moderate-to-severe AA, but targeting this pathway may still be of value in patients with mild AA as there is less of an inflammatory burden in this population. However, future larger studies may be needed to conclude apremilast's lack of efficacy in moderate-to-severe AA.

Entities:  

Keywords:  Alopecia areata; Apremilast; Moderate-to-severe AA; PDE4 inhibitor; Placebo-controlled trial

Mesh:

Substances:

Year:  2018        PMID: 30417279     DOI: 10.1007/s00403-018-1876-y

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  8 in total

1.  Off-label studies on apremilast in dermatology: a review.

Authors:  Nolan J Maloney; Jeffrey Zhao; Kyle Tegtmeyer; Ernest Y Lee; Kyle Cheng
Journal:  J Dermatolog Treat       Date:  2019-04-02       Impact factor: 3.359

2.  Immunoendocrinology: When (neuro)endocrinology and immunology meet.

Authors:  Christian A Koch; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

Review 3.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

4.  Apremilast in Refractory Alopecia Areata.

Authors:  Andrea Estébanez; Nuria Estébanez; Jose M Martín; Encarna Montesinos
Journal:  Int J Trichology       Date:  2019 Sep-Oct

Review 5.  Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.

Authors:  Cheng Zhou; Xiangqian Li; Chen Wang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-17       Impact factor: 8.667

Review 6.  Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model.

Authors:  Amos Gilhar; Rimma Laufer Britva; Aviad Keren; Ralf Paus
Journal:  J Investig Dermatol Symp Proc       Date:  2020-11

Review 7.  New and Emerging Therapies for Alopecia Areata.

Authors:  Aunna Pourang; Natasha Atanaskova Mesinkovska
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

Review 8.  Alopecia Areata: An Autoimmune Disease of Multiple Players.

Authors:  Poonkiat Suchonwanit; Chaninan Kositkuljorn; Cherrin Pomsoong
Journal:  Immunotargets Ther       Date:  2021-07-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.